VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
IMVT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
IMVTImmunovant, Inc.
$33.17$6.8B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksIMVTCash Flow

Immunovant, Inc. (IMVT) Cash Flow Statement

9Y historyFree accessUpdated daily

Operating cash flow ran at roughly 0.64 to 1.04 times net loss, with free cash flow of -$83.2M in 2027Q2 and negligible capital expenditure, indicating an asset-light model whose cash burn is largely real rather than driven by non-cash charges.

Income StatementBalance SheetCash FlowRatios

IMVT Cash Flow Statement

Annual statement

IMVT Cash Flow Statement

Immunovant, Inc. (IMVT) cash flow statement — 9-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMMar'26Mar'25Mar'24Mar'23Mar'22Mar'21Mar'20Mar'19Mar'18
Cash from Operations-395M-407.31M-375.87M-214.23M-188.19M-106.11M-83.33M-53.36M-28.55M-128.3M
Operating CF Margin %----------
Operating CF Growth %34.98%-8.36%-75.46%-13.83%-77.35%-27.34%-56.17%-86.91%77.75%-
Net Income-508.96M-505.61M-413.84M-259.34M-210.96M-156.73M-107.43M-66.39M-28.6M-136.74M
Depreciation & Amortization378K409K377K231K193K126K65K21K10K136.74M
Stock-Based Compensation50.91M55.72M49.49M41.12M32.3M34.24M06.96M1.31M1.81M
Deferred Taxes0000000000
Other Non-Cash Items105K99K133K1.13M1.13M1.11M19.47M1.24M-792K-131.55M
Working Capital Changes62.56M42.06M-12.03M2.63M-10.85M15.14M4.57M4.81M-474K1.44M
Change in Receivables-510K-1.4M2.97M-4.56M12.22M-11.72M2.5M-83K00
Change in Inventory0000000000
Change in Payables-540K-10.25M10.68M5.78M-17.12M16.25M1.25M967K00
Cash from Investing-8K-8K-759K-360K-197K-254K-210K-31K-52K0
Capital Expenditures-8K-8K-759K-360K-197K-254K-210K-31K-52K0
CapEx % of Revenue0.11%---------
Acquisitions0000000000
Investments----------
Other Investing0000000000
Cash from Financing596.22M595.76M454.49M472.43M70.89M200.13M383.11M146.97M35.58M128.3M
Debt Issued (Net)000000-3.19M37.91M00
Equity Issued (Net)596.14M596.26M450M472.75M70.5M129K386.3M000
Dividends Paid0000000000
Share Repurchases0000000000
Other Financing82K-504K4.49M-318K385K200M0109.07M35.58M128.3M
Net Change in Cash200.4M188.14M78.61M258.83M-117.28M93.67M299.57M93.59M6.99M0
Free Cash Flow-395.01M-407.32M-376.63M-214.59M-188.39M-106.37M-83.54M-53.39M-28.6M-128.3M
FCF Margin %-5567.47%---------
FCF Growth %8.42%-8.15%-75.52%-13.91%-77.11%-27.33%-56.47%-86.68%77.71%-
FCF per Share-1.91-2.23-2.48-1.55-1.53-0.97-0.95-1.24-1.99-12.83
FCF Conversion (FCF/Net Income)0.78x0.81x0.91x0.83x0.89x0.68x0.78x0.80x63720.98x0.94x
Interest Paid0000000000
Taxes Paid-51K2.39M1.2M509K00061K00

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetAdequate
Cash FlowBurning
Top Statement Risk

Continued cash burn dependence

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2027Q2)

Operating Cash Burn Tracks Losses Closely

Based on reported quarterly figures, IMVT's operating cash flow ran at roughly 0.64 to 1.04 times net loss across ten quarters, meaning non-cash charges explain only a modest share of the reported losses and cash burn is largely real.

The consistency of the operating cash flow to net income ratio near 0.8 to 0.9 suggests that the loss figures reflect genuine cash outflows rather than accounting noise. Stock-based compensation of $11M to $18M per quarter is small against losses of $87M to $153M, which reinforces that equity-based charges do not materially distort the earnings picture. Investors should treat reported losses as a reasonable proxy for underlying cash consumption rather than expecting a meaningful non-cash cushion.

Free Cash Flow Deficit Persists Without Inflection

According to reported cash flow statements, IMVT's free cash flow remained negative in every quarter shown, ranging from roughly -$76M to -$124M, with no sign of narrowing toward breakeven over the period.

Quarterly free cash flow shows no sustained improvement trend, with the 2027Q1 burn of $124.4M exceeding the first-quarter 2025 burn of $76.4M by a wide margin. Because capital expenditure is effectively nil, the burn is driven almost entirely by operating outflows tied to clinical development. This pattern suggests the funding requirement is structural and tied to program spending rather than a temporary working capital effect.

Negligible Capital Intensity Reflects Outsourced Model

As reported in financial statements, IMVT recorded capital expenditure of effectively zero to roughly $0.2M per quarter, with D&A near $0.1M, indicating an asset-light structure that relies on third parties for manufacturing and trial execution.

Near-zero capex and depreciation imply the company owns little fixed infrastructure, which is typical of a clinical-stage biologics developer dependent on contract manufacturers. This lowers the capital needs of the business but concentrates cost risk in outsourced contracts whose terms are not visible in these figures. The absence of maintenance capex means the cash burn is not being masked by infrastructure reinvestment.

Working Capital Swings Add Quarterly Volatility

Based on reported figures, IMVT's working capital changes ranged from a $41.5M inflow to a $16.0M outflow across quarters, adding meaningful noise to quarterly operating cash flow without altering the underlying burn direction.

Large swings in working capital, such as the $41.5M inflow in 2026Q4 and the $15.4M and $16.0M outflows in early 2026 and late 2025, appear to reflect timing of payables and accrued clinical expenses rather than durable cash generation. Investors should avoid annualizing any single quarter's operating cash flow, as the timing of trial-related payments may materially distort reported quarterly burn. The net effect across the period still points toward sustained consumption.

Cumulative Burn Exposes Funding Dependence

Based on the ten reported quarters, IMVT accumulated roughly $1.0B of negative free cash flow, a scale that implies continued reliance on external capital given the absence of commercial revenue offsets.

Summing the quarterly free cash flow figures yields a cumulative burn near $1.0B over roughly two and a half years, which is large relative to the company's pre-revenue profile. The pattern suggests that without commercial inflows the company must rely on equity financing or existing reserves to fund ongoing development. This warrants investigation of runway disclosures and any financing activity to assess the timing and dilution implications.

Stock Compensation Does Not Explain the Burn

Based on reported figures, IMVT's stock-based compensation of roughly $11M to $18M per quarter is far smaller than the $87M to $153M quarterly net losses, suggesting the cash burn is not an artifact of non-cash equity charges.

Because SBC is a minor fraction of losses, the apparent cash deficit is unlikely to be overstated by equity-compensation add-backs that would otherwise flatter operating cash flow. The more plausible explanation is that clinical and R&D spending drives the outflows, consistent with the earlier income statement finding that development costs dominate the operating base. Investors should instead focus on dilution risk, since a funding model reliant on equity may transfer the economic cost of the burn to shareholders through future issuances.

IMVT — Frequently Asked Questions

Quick answers to the most common questions about buying IMVT stock.

How much cash does Immunovant, Inc. (IMVT) generate from operations?

Immunovant, Inc. (IMVT) generated $-407.3M in net cash from operating activities in 2026. This reflects the cash generated directly from core business operations.

What is Immunovant, Inc.'s free cash flow?

Immunovant, Inc. (IMVT) reported negative free cash flow of $407.3M in 2026, indicating capital requirements exceeded cash from operations.

What is Immunovant, Inc.'s capital expenditure (CapEx)?

Immunovant, Inc. (IMVT) spent $0.0M on capital expenditures in 2026. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.